NEW YORK – NRGene said Tuesday that it has completed its initial public offering on the Tel Aviv Stock Exchange, raising approximately NIS 100 million ($30.6 million). The IPO values the Israeli company at NIS 370 million.
Herzog Fox & Neeman and PwC Israel advised the company on the IPO.